Compounds of Formula 1 where the variables have the meaning defined in the specification are agonists of alpha.sub.2 adrenergic receptors. Several compounds of the disclosure are specific or selective to alpha.sub.2B and/or alpha.sub.2C adrenergic receptors in preference over alpha.sub.2A adrenergic receptors. Additionally some of the claimed compounds have no or only minimal cardiovascular and/or sedatory activity. The compounds of Formula 1 are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha.sub.2 adrenergic receptors. Compounds of Formula 1 which have no significant cardiovascular and/or sedatory activity are useful for treating pain and other conditions with minimal side effects.